Skip to main content

Implementing an electronic health record dashboard for safe anticoagulant management: learning from qualitative interviews with existing and potential users to develop an implementation process

A Correction to this article was published on 13 March 2023

This article has been updated



Facilitating appropriate care delivery using electronic health record (digital health) tools is increasing. However, frequently used determinants frameworks seldom address key barriers for technology-associated implementation.


Semi-structured interviews were conducted in two contexts: the national Veterans Health Affairs (VA) following implementation of an electronic dashboard, a population health tool, and the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) prior to implementation of a similar electronic dashboard. The dashboard is designed for pharmacist or nurse use to monitor safe outpatient anticoagulant prescribing by physicians and other clinicians We performed rapid qualitative inquiry analysis and selected implementation strategies. Through a stakeholder focus group session, we selected implementation strategies to address determinants and facilitate implementation in the MAQI2 sites.


Among 45 interviewees (32 in VA, 13 in MAQI2), we identified five key determinants of implementation success: (1) clinician authority and autonomy, (2) clinician self-identity and job satisfaction, (3) documentation and administrative needs, (4) staffing and work schedule, and (5) integration with existing information systems. Key differences between the two contexts included concerns about information technology support and prioritization within MAQI2 (prior to implementation) but not VA (after implementation) and concerns about authority and autonomy that differed between the VA (higher baseline levels, more concerns) and MAQI2 (lower baseline levels, less concern).


The successful implementation of electronic health record tools requires unique considerations that differ from other types of implementation, must account for the status of implementation, and should address the effects of the tool deployment on clinical staff authority and autonomy. Interviewing both post-implementation and pre-implementation users can provide a robust understanding of implementation determinants.

Peer Review reports


A potential benefit of rapidly growing electronic health record (EHR) use in medicine is the capacity to implement evidence-based, EHR-guided clinical decision support tools, such as the use of best practice alerts (clinical reminders) and population-level dashboards [1,2,3]. While best practice alerts are typically designed for specific patient-provider interactions, population-level dashboards allow clinicians and/or clinical leaders to survey a large cohort of patients to identify key trends in care delivery. However, few evaluations have addressed the operational and social implementation barriers of these tools for clinical staff. Additionally, how well an electronic tool developed in one clinical setting can be adapted and implemented in an alternative setting remains largely unknown. To better understand these challenges, we set out to study the implementation of a population health dashboard for safe anticoagulant prescribing and monitoring in two distinct settings, one of which was already using the dashboard, the other was not.

All anticoagulant drugs are high-risk/high-benefit medications that are essential for preventing life-threatening complications, such as stroke and other thrombotic conditions [4]. For more than five decades, warfarin was the only available oral anticoagulant in the USA and much of the world. While effective at preventing blood clots, warfarin has a high risk of harm and is burdensome to dose and monitor [4]. Since 2010, oral anticoagulant prescribing has been slowly transitioning from warfarin to newer direct oral anticoagulants (DOACs) [5,6,7,8]. This shift has led to a substantial change in who manages anticoagulation prescription changes and how closely patients are followed. Specifically, patients on warfarin are often monitored at least every month to ensure appropriate dosing and drug levels. However, DOAC medications are prescribed using fixed doses without any dosing or drug level monitoring. Therefore, DOAC-treated patients typically do not have frequent interactions with anticoagulation experts, such as nurses and pharmacists working in anticoagulation clinics.

While safer and dramatically simpler to dose and monitor than warfarin, accurate DOAC prescribing is still complicated and adverse events due to incorrect dosing remain relatively common. In fact, multiple studies have identified that as many as 1 in 7 patients have inappropriate DOAC prescriptions [9,10,11,12]. Common prescribing issues include failure to adjust medication dosing appropriately for kidney or liver disease, failure to recognize potential drug-drug interactions, and failure to adjust dosing for different clinical indications as appropriate. When DOACs are mis-dosed, patients are at markedly increased risk for costly and potentially deadly bleeding or thrombotic/stroke complications.

To ensure the safe use of high-risk medications, many health systems are attempting EHR-guided population health management programs. One promising method is the use of dashboards, such as the one created by a small team of pharmacists and programmers at the United States Department of Veterans Affairs (VA) health system [13, 14]. This DOAC Dashboard assists anticoagulation pharmacists by identifying every VA patient who is prescribed a DOAC and performs an asynchronous screen from a pre-defined set of alerts for potentially risky prescribing. The tool then allows a pharmacist to click on an individual patient record, review the details of their DOAC prescribing and reason for an alert, and take an action. The DOAC Dashboard’s software interface was made available to all VA pharmacists in 2017. However, the decision to use or not use the DOAC Dashboard (site-level adoption) was left up to individual VA sites/clinics. Support for implementation was provided by the DOAC Dashboard programmer and a small team of experienced users through a nation-wide list-serve. Currently, the DOAC Dashboard is now in regular use by almost all VA anticoagulation pharmacists nation-wide, but with varying frequency of use and models for how it is incorporated into clinical workflow.

The implementation successes and failures of the DOAC Dashboard have not been clearly evaluated. Furthermore, many technological solutions in healthcare have failed to address operational and social barriers and the potential replicability of the digital tool’s implementation in sites other than VA are totally unknown. Therefore, we set out to discover the negative and positive determinants (barriers and facilitators) to effective use of the DOAC Dashboard for VA users as well as the determinants among potential non-VA users in a quality improvement initiative in the state of Michigan, USA [14]. Our goal was to use the VA experience to inform effective Dashboard introduction in a diverse set of hospital systems. We used theory-guided determinants interviews of current VA users of the dashboard and potential users in different health systems to identify promising implementation strategies.


Settings and participants

This project leverages two health care contexts. The first is the United States VA health system. The VA is the largest vertically and horizontally integrated health system in America [15]. Serving over 9 million veterans, it offers services at over 150 medical centers and over 1000 outpatient clinics. At the time of the interviews, the DOAC Dashboard had been available to all VA pharmacists for up to 3 years. Most participants from this setting were specialist anticoagulation pharmacists, which matches how anticoagulation care is provided in the VA health system. We also interviewed pharmacy technicians, and clinic managers who work in ambulatory anticoagulation clinics as well as the programmer who developed the VA DOAC Dashboard. Participants were identified by clinic managers and invited to participate through e-mail communication.

The second setting includes four distinct health systems that participate in the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). Participating centers include both university-affiliated and independent centers located in urban and suburban regions of Michigan, USA. Each center has an anticoagulation clinic staffed by nurses and/or pharmacists operating under physician leadership. The participants from this setting came from a wider variety of professional backgrounds, including physician champions and medical directors, nurses and pharmacists who work in the ambulatory anticoagulation clinics, and anticoagulation clinic managers. This matches the range of caregivers who provide anticoagulation care in the MAQI2 sites. Most of the participants are active members of the MAQI2 consortium or were identified as important stakeholders by the MAQI2 leaders for each site. Development of a non-VA DOAC Dashboard was planned for MAQI2 sites at the time of the interviews.

In addition to the differences in clinical settings between the VA and MAQI2 sites, another important distinction is that the VA sites all had access to the DOAC Dashboard (and most were experienced users) at the time of the interviews while the MAQI2 sites had not yet implemented their dashboard.

Implementation intervention development

For the larger intervention project, we are following a 7-step process to develop our implementation intervention (Table 1). This approach is similar to implementation mapping as described by Fernandez et al. and utilized recently by Klaiman et al. [16, 17] This manuscript describes steps 3–6 of the process (interviews, analysis, implementation strategy selection, and stakeholder feedback), which focus on understanding the determinants of effective implementation and guide implementation intervention development. Additional methodological details are available in the online Additional file 1 supplemental appendix. Steps 1 and 2, creating the team and identifying the intervention, preceded this work. The team was developed based on clinical and quality improvement experience related to anticoagulation care or electronic health record tool development. Many team members (physician, pharmacist, information technology programmer) has previously worked together on related projects. Other team members (project manager, qualitative expert) have not previously worked on a project in this clinical area.

Table 1 Implementation approach to dashboard development in MAQI2

Data collection (Step 3)

Our semi-structured interview guides (both for VA and MAQI2) were developed using pre-specified constructs from the Consolidated Framework for Implementation Research (CFIR) in addition to the Technology Acceptance Model (TAM) framework (Additional file 1 supplemental appendix) [19, 20]. The implementation team (GDB, ES, AS, JS) reviewed sample interview questions from and published literature using TAM. Questions that were anticipated to be relevant to this project were adapted. The overall interview guide was then tested with two preliminary interviewees and edits were made to improve flow and clarity. VA sites were selected based on their level of DOAC Dashboard use (high, moderate, low/none) as calculated by the number of days per month with one or more pharmacists accessing the DOAC Dashboard. We also selected key VA sites where DOAC Dashboard use had changed significantly between 2017 and 2019 (e.g., high-to-low) to assess what specific determinants influenced the change in usage. All four MAQI2 sites who currently manage DOAC patients were interviewed. We identified participants at each site (VA and MAQI2) by asking managers to identify key front-line clinical staff.

Interviews were conducted by trained research staff (ES and AR). All participants provided verbal consent to participate and for the interviews to be recorded. Recordings were transcribed and anonymized by removing participant and site names. The interviewees collected notes during and after each interview, following the rapid qualitative analysis approach.

Rapid qualitative analysis (step 4)

We undertook a rapid qualitative analytic approach that incorporated elements of a template analysis by using pre-existing codes from CFIR and TAM [21,22,23]. The three qualitative researchers (ES, AR, LT) reviewed notes taken during the interviews as well as the transcribed interviews to identify relevant themes. These were done using both pre-defined codes related to individual CFIR and TAM constructs as well as any newly emergent themes from the interviews.

Selection of implementation strategies (step 5)

A table of key determinants identified from the interviews was created and organized according to frequency and importance, as determined by the implementation team through reviews of the interview transcripts (counting the number of coded themes) and group discussion until consensus was reached about importance. Following this prioritization activity, implementation strategies from the Expert Recommendations for Implementation Change (ERIC) project were reviewed and potential strategies were selected by the implementation team to match each prioritized determinant [24]. Additional implementation strategies suggested in the stakeholder interviews were also included.

Stakeholder feedback on implementation strategies (step 6)

The list of prioritized determinants identified from the interviews along with suggested implementation strategies were shared with key MAQI2 stakeholders. Prioritization was determined by the team members based on the frequency and importance (determined in step 5) and the feasibility of paired implementation strategies selected and adapted from the ERIC project list [24]. During this session, two team members (ES and GDB) presented findings from the interviews and analysis along with a list of potential implementation strategies. Stakeholders from each MAQI2 site provided feedback as to the feasibility and prioritization for individual strategies.

This project was reviewed and approved by the institutional review boards of both the University of Michigan and the Ann Arbor VA.


VA interview findings

Interviews were conducted with 32 stakeholders across 22 VA sites (Table 2). Interviews lasted an average of 38 min (range 22–61 min).

Table 2 Characteristics of the interviewees

Five key determinants of implementation success were identified during rapid qualitative analysis of the VA transcripts. These included (1) clinician authority and autonomy; (2) clinician self-identity and job satisfaction; (3) documentation, communication, and administrative needs; (4) staffing and work schedule; and (5) technology integration (Table 3).

Table 3 Determinants of implementation success and associated implementation strategies

Clinician authority and autonomy were commonly identified determinants of implementation success at VA sites. Specifically, staff expressed a strong desire to control their own workflow and identify ways for the DOAC Dashboard to fit into their pre-existing workflow. Stakeholder interviewees also expressed concerns about the level of autonomy they would have for making guideline recommended DOAC dose changes when the DOAC Dashboard alerted them to an unsafe prescription. This was particularly troubling for some pharmacists when they had to alert a prescribing clinician rather than make the change themselves. Once they were aware of a DOAC dosing error, they found a lack of autonomy limited their ability to enact meaningful changes if the prescribing clinician did not promptly respond to their messages. They noted that without the knowledge of a DOAC prescribing error identified by the DOAC Dashboard, they would not feel an obligation to “fix” the prescribing error. Importantly, the issue around autonomy was not a direct result of the DOAC Dashboard but rather the variation in practice authority and autonomy given to pharmacists or nurses across the USA.

Clinician self-identity and job satisfaction was closely linked to how robustly they integrated the DOAC Dashboard into their practice. Some pharmacists expressed a concern that the computer is replacing their clinical judgement or justification for their work. Furthermore, many VA pharmacists who were used to seeing patients face-to-face feared the loss of direct patient care if they no longer had scheduled visits and instead relied only on the DOAC Dashboard to identify potential dosing errors.

Documentation and work performance barriers were commonly cited by many VA stakeholder interviewees. These include difficulties communicating with primary care providers and specialists both within and outside the VA health system, a problem that is not unique to the DOAC Dashboard itself and often requires additional staff time to complete. They also expressed concern that staff performance measures may not include DOAC Dashboard work if there is not sufficient documentation to account for the time spent reviewing charts and communicating with other clinicians or the patient.

Having sufficient staff and scheduled time to work with the DOAC Dashboard was a common determinant of implementation success. Stakeholder interviewees who felt the DOAC Dashboard was highly successful tended to describe a workflow that included dedicated staff and time to review the dashboard and make clinically appropriate changes. This included interviewees at sites that developed pure “dashboard clinics,” days in which the pharmacists would work primarily on addressing flags. This would allow them to extend the length between visits for patients who did not have flags. In distinction, stakeholder interviewees that expressed difficulty using the dashboard often worked at sites where the DOAC Dashboard was added to existing workflow. This was particularly true when sites first began using the DOAC Dashboard because of the large number of alerts they encountered. Over time, this number was reduced, and interviewees reported a manageable “steady state.”

Lastly, additional concerns about integration with existing information systems were cited by some VA interviewees. Two major areas were highlighted, including uncertainty around accuracy of the tool and the speed with which it loads and can be used. Some pharmacists expressed a lack of trust in the dashboard, finding it not always accurate and missing individual patients for whom the dashboard did not show an alert. This was seen as a barrier for clinicians used to reviewing every patient that they followed on a regular basis.

Comparison of VA and MAQI2 interview findings

Thirteen stakeholders at four MAQI2 sites participated in interviews (Table 2). These interviews lasted an average of 42 min (range 27–50).

Four of the five determinants from the VA interviews were identified in the MAQI2 interviews. These included (1) clinician authority and autonomy; (2) documentation, communication, and administrative needs; (3) staffing and work schedule; and (4) integration with existing information systems (Table 3). Clinician self-identity and job satisfaction were not identified in the MAQI2 interviews. Opinions on documentation and administrative needs and staffing and work schedule identified by MAQI2 interviewees were very aligned with those of their VA counterparts. Clinician authority and autonomy and technology were notable differences, as detailed below.

Regarding authority and autonomy, the MAQI2 stakeholders identified that regulatory barriers would need to be addressed in ways that were not identified in the VA interviews (Table 3). Specifically, the nurses and pharmacists in the MAQI2 centers work under collaborative agreements with specific physician groups at their hospitals. Currently, very few patients treated with DOACs are individually referred to the anticoagulation clinic for nurse and/or pharmacist monitoring. To maximize impact, the MAQI2 DOAC Dashboard is designed to monitor all DOAC-treated patients across a health system or who are managed by large groups of physician organizations, not just those who were specifically referred to the anticoagulation clinic for monitoring. Therefore, many of those agreements will need to be updated so that all DOAC-treated patients within a health system can be managed by the nurses and/or pharmacists in the anticoagulation clinic without individual referral. Furthermore, the DOAC Dashboard can only be used for patients who are being managed by physicians with existing anticoagulation clinic practice agreements and cannot be used to monitor patients managed by other physician groups within the hospital or health system. This is notably different than the VA system, which as a federal agency of the US government operates under very different rules and regulations from non-federal health systems. Non-VA nurses and pharmacists are required to operate under individual state rules and regulations as well as often working with independent, self-employed physician groups.

Technological concerns were even more salient in the MAQI2 interviews than in the VA. In particular, concerns about reliability/trust in the accuracy of the tool and the speed with which the tool loaded (Table 3) were very prevalent. Interviewees did not identify resources or time needed to initially implement the DOAC Dashboard as a major barrier. Unlike in VA, the MAQI2 interviews frequently cited concerns with how limited access to dedicated information technology staff members who are ultimately responsible for any changes to the electronic health record system. Specifically, they felt that the limited access to these professionals would harm the adoption of the dashboard and how implementing the dashboard into the electronic health record might burden those information technology staff from other immediate needs. They also frequently cited concerns about a lack of access to medical records from outside their health system, a barrier not frequently noted by VA interviewees due to availability of a nation-wide VA EHR records.

Implementation strategy selection and stakeholder feedback

Based on the findings from both the VA and MAQI2 interviews, our implementation team identified a set of strategies aimed at addressing key determinants of successful implementation (Table 4). These strategies were prioritized based on the relative frequency of their targeted determinant and feasibility. These were reviewed and endorsed by the MAQI2 stakeholder focus group with broad and enthusiastic support regarding feasibility and impact.

Table 4 Strategies for MAQI2 implementation endorsed by stakeholder group

To address concerns about control over each individual’s personal workflow to use the DOAC Dashboard effectively (authority and autonomy), the MAQI2 stakeholders agreed that multi-disciplinary teams should pilot and revise workflows as needed. To accomplish this work, new clinical teams will need to be created, leveraging pharmacists, nurses, pharmacy technicians, and administrative assistants. Furthermore, sites agreed to create clinic-led medication change guidelines and to update institutional policies that allow anticoagulation clinic staff to change unsafe DOAC dosing or use.

Within the MAQI2 sites, technological issues, specifically fears of long loading times and the tool’s accuracy, were the most commonly cited potential barrier to a successful use of the DOAC Dashboard. To address these concerns, implementing sites decided to work with a central IT programmer to promote local technical expertise and assistance as well as virtual visits to early adopter sites. Rapid cycling to make changes when clinical guidance evolves (e.g., changes in approved DOAC indications) is a high priority for the MAQI2 implementation team. Finally, trialability with the DOAC Dashboard will be encouraged to build trust in the digital tool at each MAQI2 site. Specifically, after technical implementation, sites will have an opportunity to trial use of the DOAC Dashboard before developing clinical protocols. During this trial, the MAQI2 programmer will be available for technical support and all MAQI2 sites will be encouraged to provide peer support through regular monthly conference calls.

While many implementation projects draw from a robust list of implementation strategies targeted to specific determinants, this project had to identify strategies that were unique to technology-based implementation. The central IT programmer is familiar with the design of the dashboard and will assist both local clinical and IT partners with technological implementation. He is also able to identify technical problems at one site and quickly disseminate potential solutions at the other sites. Unlike many implementation projects that do not rely heavily on IT tools, this project requires unique skills that rarely are found within clinical champions. Therefore, it is paramount that the IT and clinical teams work closely together to achieve successful implementation.


Through interviews with 45 diverse stakeholders, we identified five key determinants of implementation success for an EHR-based tool for safe medication use. These include clinician authority and autonomy, clinician self-identity and job satisfaction, documentation/communication and administrative issues, staffing and scheduling, and integration with existing information systems. These concerns were similar for the VA providers who have been using the dashboard as for the MAQI2 providers who will be adopting the tool. For each set of important implementation determinants, we have also identified key implementation strategies that our stakeholder group feel are feasible and impactful. Many of these have already been successfully used at some or all MAQI2 sites.

Differences between VA and MAQI2 interviews

Two important distinctions between the VA and MAQI2 interviews warrant discussion. First, clinician self-identity and job satisfaction were not identified as a concern in the MAQI2 interviews. Though this issue may emerge after the MAQI2 complete implementation, it may reflect important differences between the VA and MAQI2 anticoagulation clinics and their staff. In the VA, most anticoagulation clinic staff are pharmacists who practice at the top of their license. While phone-based contact with patients is used, face-to-face anticoagulation care is quite common. Additionally, many anticoagulation clinics in the VA serve not only to adjust warfarin dose based on monthly labs, but they also support perioperative management and assist with other related care practices. In contrast, at the four MAQI2 anticoagulation clinics, the clinicians are predominantly nurses, all care is phone-based, and patients prescribed DOAC medications are rarely referred for care to the anticoagulation clinic. As a result, the clinical training and work tasks most common in each setting may dictate the importance (or presence) of certain implementation determinants for new programs that aim to fundamentally change the way clinical care is delivered.

The second important difference was that only MAQI2 interviewees expressed strong concerns with the availability of sufficient information technology (IT) resources and ability to prioritize this digital tool project. Many MAQI2 interviewees shared concerns with prior EHR implementation efforts that were not accomplished as quickly as desired. This likely reflects that the DOAC Dashboard had not yet been implemented at these centers when the interviews occurred, while all VA interviewees had used the VA Dashboard. This shows how much the timing of an assessment is an important consideration for comparing experienced to novice users or sites in any implementation project. Concerns about IT programmer workload and prioritization for IT implementation have been identified as important barriers in similar work across other clinical domains [25]. While decentralized technology-associated solutions (e.g., SMART on FHIR application programming interface) have been proposed to reduce the programmer burden at individual sites, these tools are not yet widely implemented at many health centers. Furthermore, institutional leaders (e.g., chief medical information officers) have variable desire to control the logic and flow of information when digital tools are implemented outside of (but interfacing with) their EHR system.

Impact beyond the DOAC Dashboard

Our work has proven very helpful as we prepare to implement the DOAC Dashboard within the MAQI2 centers. We also hope that this can become a generalized approach to high-stakes technological implementations in other spheres of medicine. While much work in implementation science has focused on the use of non-electronic interventions, there has been less focus understanding how to effectively operationalize and use digital tools as implementation strategies aimed at promoting safe and effective medication management [26, 27]. Emblematic of this, commonly used determinant frameworks include very few items specific to technology [18, 19, 28]. Specifically, CFIR does not include information technology/systems as a construct in its current form while the Tailored Implementation of Chronic Diseases checklist has a single item for “Information System.” In contrast, emerging health information technology frameworks are being developed to detail the numerous factors that influence successful EHR- and technology-based implementation within health care delivery [29, 30]. Integrating these frameworks/checklists is an important area of future research.

Similarly, compiled lists of implementation strategies do not include a diverse array of technology-associated options [24]. Nonetheless, healthcare delivery in the twenty-first century is becoming increasingly dependent on technology with the rapid adoption of EHRs in both the hospital- and ambulatory-care settings. Our project, which aims to leverage EHR technology to facilitate safe anticoagulant prescribing, is just one example of how clinicians can leverage technology to ensure evidence-based practices are followed. Notably, three distinct etiologies of implementation determinants were identified from our stakeholder interviews: (1) variation in external environments/policies that differentially limit pharmacist or nurse autonomy, (2) direct effect of the digital tool on how clinicians view their decision-making capacity, and (3) interaction between clinician workflow/environment and the digital tool.

The second issue parallels commonly cited barriers by many physicians who see guidelines as limiting individual clinical judgement in favor of “cookbook medicine.” [31, 32] Future work should explore how technology serves both as a determinant of implementation success (i.e., resources required to install and use the DOAC Dashboard) and how it can be used as a strategy to overcome key barriers (i.e., use a DOAC Dashboard to identify overlooked prescribing errors by non-experts). This work will likely require that technology-associated efforts are described in detail so that the individual elements can be tested for impact on evidence-based practice.

Our implementation intervention development has important limitations that must be acknowledged. First, most of our stakeholder interviews were conducted with VA clinicians who were identified by clinic managers. It is not yet clear how well these experiences translate to the non-VA healthcare setting. We plan to conduct post-implementation interviews with MAQI2 stakeholders to assess for any important differences. We also cannot exclude a potential for selection bias in our participants. However, the large number of interviews and intentional inclusion of sites with varied DOAC Dashboard use should minimize this impact. Second, while the MAQI2 DOAC Dashboard was developed to closely mirror the VA DOAC Dashboard, it is inherently different given the different EHR systems. However, the underlying elements (patient identification, rules for medication alerts) are the same and therefore should not meaningfully impact the implementation or evaluation. Third, while we often included multiple interviewees from a single site, some sites were only able to identify a single stakeholder to participate in the interview. Finally, the findings from this study may not be applicable to the development and implementation of other EHR-based tools for other medications or clinical care delivery. For instance, not all medications have such complex dosing regimens (e.g., anti-hypertensive medications) or are titrated based on factors not commonly collected within the electronic health record (e.g., anxiety symptom control).


In summary, we have identified several key operational and social barriers to EHR tool implementation within the health care system. Using a theory-informed process, we have developed a set of implementation interventions aimed at improving evidence-based anticoagulant prescribing using an EHR-based population health tool. Future work will evaluate this implementation intervention in a diverse set of health systems. Additional work to better incorporate granular technology issues in key implementation determinants frameworks and implementation strategies lists will greatly benefit teams looking to leverage this powerful and rapidly expanding healthcare tool.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to the Department of Veterans Affairs’ regulatory compliance.

Change history



Consolidated Framework for Implementation Research


Direct oral anticoagulant


Electronic health record


Information technology


Michigan Anticoagulation Quality Improvement Initiative


Technology acceptance model


Veterans affairs


  1. Austin J, Barras M, Sullivan C. Interventions designed to improve the safety and quality of therapeutic anticoagulation in an inpatient electronic medical record. Int J Med Inform. 2020;135:104066 Available from:

    Article  PubMed  Google Scholar 

  2. Allen AL, Lucas J, Parra D, Spoutz P, Kibert JL, Ragheb B, et al. Shifting the paradigm: a population health approach to the management of direct oral anticoagulants. J Am Heart Assoc. 2021:e022758 Available from:

  3. Bejjanki H, Mramba LK, Beal SG, Radhakrishnan N, Bishnoi R, Shah C, et al. The role of a best practice alert in the electronic medical record in reducing repetitive lab tests. Clin Outcomes Res. 2018;10:611–8.

    Article  Google Scholar 

  4. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–507.

    Article  PubMed  Google Scholar 

  5. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498 Available from:

    Article  PubMed  Google Scholar 

  6. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R. J Am Coll Cardiol. 2019;74:104–32 Available from:

    Article  PubMed  Google Scholar 

  7. Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693–738 Available from:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Renner E, Barnes GD. Antithrombotic management of venous thromboembolism: JACC focus seminar. J Am Coll Cardiol. 2020;76:2142–54.

    Article  CAS  PubMed  Google Scholar 

  9. Camm AJ, Cools F, Virdone S, Bassand JP, Fitzmaurice DA, Arthur Fox KA, et al. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol. 2020;76:1425–36.

    Article  CAS  PubMed  Google Scholar 

  10. Gregory H, Cantley M, Hall GA, Matuskowitz AJ, Weant KA. Incidence of anticoagulation medication prescribing errors in patients discharged from the emergency department. J Am Coll Clin Pharm. 2020:1–6.

  11. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68:2597–604 Available from:

    Article  CAS  PubMed  Google Scholar 

  12. Dawson T, Decamillo D, Kline-Rogers E, Haymart B, Froehlich JB, Barnes GD. Correcting inappropriate prescribing of direct oral anticoagulants: a population health approach. Res Pr Thromb Haemost. 2018;2:229.

    Google Scholar 

  13. Rossier C, Spoutz P, Schaefer M, Allen A, Patterson ME. Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management. J Thromb Thrombolysis. 2020; Available from:

  14. Valencia D, Spoutz P, Stoppi J, Kibert JL 2nd, Allen A, Parra D, et al. Impact of a direct oral anticoagulant population management tool on anticoagulation therapy monitoring in clinical practice. Ann Pharmacother. 2019;2019(1060028019835843) Available from:

  15. About VHA - Veterans Health Administration [Internet]. [cited 2020 Jul 23]. Available from:

  16. Fernandez ME, ten Hoor GA, van Lieshout S, Rodriguez SA, Beidas RS, Parcel G, et al. Implementation mapping: using intervention mapping to develop implementation strategies. Front Public Heal. 2019;7:1–15.

    Google Scholar 

  17. Klaiman T, Silvestri JA, Srinivasan T, Szymanski S, Tran T, Oredeko F, et al. Improving prone positioning for severe acute respiratory distress syndrome during the covid-19 pandemic an implementation-mapping approach. Ann Am Thorac Soc. 2021;18:300–7.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Flottorp SA, Oxman AD, Krause J, Musila NR, Wensing M, Godycki-Cwirko M, et al. A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice. Implement Sci. 2013;8:35 Available from:

    Article  PubMed  PubMed Central  Google Scholar 

  19. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50 Available from:

    Article  PubMed  PubMed Central  Google Scholar 

  20. Holden RJ, Karsh BT. The technology acceptance model: its past and its future in health care. J Biomed Inf. 2009;2010(43):159–72 Available from:

    Google Scholar 

  21. Beebe J. Rapid Qualitative Inquiry. 2nd ed: Rowman & Littlefield; 2014.

    Google Scholar 

  22. Brooks J, McCluskey S, Turley E, King N. The utility of template analysis in qualitative psychology research. Qual Res Psychol. 2015;2015(12):202–22 Available from:

    Article  Google Scholar 

  23. McIlvennan CK, Morris MA, Guetterman TC, Matlock DD, Curry L. Qualitative methodology in cardiovascular outcomes research: a contemporary look. Circ Cardiovasc Qual Outcomes. 2019;12:e005828 Available from:

    Article  PubMed  Google Scholar 

  24. Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci. 2015;10:21 Available from:

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gesell SB, Golden SL, Limkakeng AT, Carr CM, Matuskowitz A, Smith LM, et al. Implementation of the HEART pathway: using the consolidated framework for implementation research. Crit Pathways Cardiol A J Evidence-Based Med. 2018;17:191–200 Available from:

    Article  Google Scholar 

  26. Barnes GD, Misirliyan S, Kaatz S, Jackson EA, Haymart B, Kline-Rogers E, et al. Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics. Implement Sci. 2017;12:87 Available from:

    Article  PubMed  PubMed Central  Google Scholar 

  27. Greiver M, Dahrouge S, O’Brien P, Manca D, Lussier MT, Wang J, et al. Improving care for elderly patients living with polypharmacy: protocol for a pragmatic cluster randomized trial in community-based primary care practices in Canada. Implement Sci. 2019;14:1–15.

    Article  Google Scholar 

  28. Cane J, O’Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7:37 Available from:

    Article  PubMed  PubMed Central  Google Scholar 

  29. Singh H, Sittig DF. Measuring and improving patient safety through health information technology: the health IT safety framework. BMJ Qual Saf. 2016;25:226–32.

    Article  PubMed  Google Scholar 

  30. Singh H, Sittig DF. A sociotechnical framework for safety-related electronic health record research reporting: the SAFER reporting framework. Ann Intern Med. 2020;172:S92–100.

    Article  PubMed  Google Scholar 

  31. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud P-AC, et al. Why don’t physicians follow clinical practice guidelines? JAMA. 1999;282:1458 Available from:

    Article  CAS  PubMed  Google Scholar 

  32. Bierbaum M, Rapport F, Arnolda G, Nic Giolla Easpaig B, Lamprell K, Hutchinson K, et al. Clinicians’ attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literature. Implement Sci. Implement Sci. 2020;15:1–24.

    Article  Google Scholar 

Download references





Funding for this project from the Agency for Healthcare Research and Quality (R18HS026874). The funders had no role in the study design, data collection, analysis or interpretation, decision to publish, or preparation of this manuscript.

Author information

Authors and Affiliations



GDB drafted the manuscript. ES and AR conducted the interviews. GDB, ES, AR, LT, and JS conducted the analyses and provided critical revisions to the manuscript. ML, MD, and AS provided critical revisions to the manuscript. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Geoffrey D. Barnes.

Ethics declarations

Ethics approval and consent to participate

Regulatory approval was obtained from the Ann Arbor VA and University of Michigan institutional review boards. Verbal informed consent was obtained from each interviewee.

Consent for publication


Competing interests

Dr. Barnes discloses consulting fees from Pfizer/Bristol Myers Squibb and Janssen. Dr. Dorsch is supported by R18 HS026874 and R21 HS026322 from the Agency for Health Research and Quality, R01 AG062582 from the National Institutes of Health (NIH)/National Institute of Aging, and the American Health Association Health IT Research Network; has received honoraria from Janssen; and has received research funding from Bristol Myers Squibb/Pfizer and Amgen in the past 2 years. The other authors have no disclosures. The authors declare that Anne Sales is co-Editor-in-Chief of the journal.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Additional Methodological Detail.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barnes, G.D., Sippola, E., Ranusch, A. et al. Implementing an electronic health record dashboard for safe anticoagulant management: learning from qualitative interviews with existing and potential users to develop an implementation process. Implement Sci Commun 3, 10 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: